Your CDx Partner from Translational Research to Global Commercialization

We collaborate closely with our pharma partners to help accelerate access to treatment by ensuring companion diagnostic testing readiness in the relevant markets at launch.

You can depend on a team of proven, IVD-experienced project managers, highly qualified scientists, manufacturing, quality and regulatory experts. Our commercial team works with us in tandem, enabling us to move seamlessly through each phase - from R&D through clinical and commercialization. All teams have a deep understanding of the oncology testing landscape.

Together, we ensure that product design requirements reflect customer and market needs from an analytic performance, end-user and economic perspective.

The expertise and global reach to support your success

Compliance with international regulations, filing and marketing
Global launch strategies for the companion diagnostic
Market access and reimbursement strategies
KOL programs to drive market awareness and readiness for the diagnostic test
Medical education programs and organizing lab staff training
Direct sales force and distributor partner network, leveraging key relationships with MDx end users, pathologists, and purchasers in over XX countries globally to support your success

Advancing precision oncology requires effective biomarker testing and actionable insights that drive better patient outcomes. With next-generation sequencing (NGS) testing in your hospital, you can get the insights you need when you need them - in days, not weeks.

One size does not fit all

Extensive tools menu spans all stages of drug development

Global presence

>600 labs in across the world rely on our technology

Worldwide CDx expertise

CDx approvals in multiple countries and continents

A spectrum of NGS oncology solutions

In oncology clinical research, a single solution can never fit all the different interactions, samples, and tumors to be tested.

That's why we equip you with a whole spectrum of solutions for tumor profiling from FFPE tissue samples to liquid biopsy.

Making precision oncology possible. Together.

Our streamlined end-to-end workflows, relevant test menus, and support are empowering laboratories around the world to adopt NGS and move precision oncology forward.

Multi-biomarker testing, a new paradigm

Oncomine Dx Target Test was the first, and is still the only commercially distributable multiple biomarker CDx test based on NGS, which can be implemented in new laboratories around the world.

Click one of the icons below to download a PDF for your country.

Enabling global access to testing

Oncomine Dx Target Test was approved by the FDA in 2017, followed by self-declaration and launch of a CE marked version in Europe and approval in South Korea in 2018, and by MHLW in Japan in 2019.

Subscribe here for interesting and important news about NGS in precision oncology

Have questions, ready to speak to a representative about brining NGS to your lab?

Contact a representative

*The Oncomine Dx Target Test is For in Vitro Diagnostic Use.

(https://www.oncomine.com)

Trademarks (https://www.thermofisher.com/us/en/home/global/trademark-information. html | Terms and Conditions (http://www.thermofisher.com/us/en/home/global/terms-and-conditions.html | Privacy Notices (https://www.thermofisher.com/us/en/home/global/privacy-policy.html)